Table III.

Comparison of responses to atezolizumab plus bevacizumab between the high-level and low-level CD8⁺ tumor infiltrating lymphocytes groups.

Response	All (n=24)%	High-level CD8+ TILs (n=12)%	Low-level CD8+ TILs (n=12)%	P-value
Overall Response				0.189
CR	0 (0)	0 (0)	0 (0)
PR	12 (50)	8 (66.6)	4 (33.3)
SD	4 (16.7)	2 (16.7)	2 (16.7)
PD	8 (33.3)	2 (16.7)	6 (50)
ORR (CR+PR)	12 (50)	8 (66.6)	4 (33.3)	0.012
DCR (CR+PR+SD)	16 (66.7)	10 (83.3)	6 (50)	0.031

TILs, tumor-infiltrating lymphocytes; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate; DCR, disease control rate.